09.09.13
Positive initial results of the ongoing human clinical studies for the efficacy of kollaGen II-xs have been released. The ingredient from Certified Nutraceuticals, Inc. (under U.S. Patent #8,344,106 B1- Avian Sternum Collagen Type II powder Hydrolysate) is a natural blend of Mucopolysaccharide compounds and amino acids— the building blocks of joint cartilage. According to the initial findings, the compositional makeup of kollaGen II-xs has demonstrated therapeutic value for connective tissue disorders and improved the mobility and activity for individuals with joint conditions.
The study examined 15 patients ages 17 years to 81 years (8 males/7 females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered was 1500mg - 2500mg daily, taken with citric juice on an empty stomach. All participants could not walk/jog 300 meters without pain occurring in some form.
Supplementation with kollaGen II-xsproduced a significant treatment response at seven days for flexibility (33.3% increase; P = 0.037) and at 30 days for general pain (87.9% reduction; P = 0.007), flexibility (62.4% increase; P = 0.005) and range of motion associated pain (76.1% reduction; P = 0.021). The substantial treatment response continued through 30 days for pain (70.6% reduction; P = 0.0001). There were no adverse events reported during the study and the treatment was reported to be well tolerated by study participants.
According to Certified Nutraceuticals, the results demonstrate that kollaGen II-xsmay be a viable treatment option for the management of joint and connective tissue disorders.
For more information: www.certifiednutra.com
The study examined 15 patients ages 17 years to 81 years (8 males/7 females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered was 1500mg - 2500mg daily, taken with citric juice on an empty stomach. All participants could not walk/jog 300 meters without pain occurring in some form.
Supplementation with kollaGen II-xsproduced a significant treatment response at seven days for flexibility (33.3% increase; P = 0.037) and at 30 days for general pain (87.9% reduction; P = 0.007), flexibility (62.4% increase; P = 0.005) and range of motion associated pain (76.1% reduction; P = 0.021). The substantial treatment response continued through 30 days for pain (70.6% reduction; P = 0.0001). There were no adverse events reported during the study and the treatment was reported to be well tolerated by study participants.
According to Certified Nutraceuticals, the results demonstrate that kollaGen II-xsmay be a viable treatment option for the management of joint and connective tissue disorders.
For more information: www.certifiednutra.com
